GlassScriptPhysician profile
Oren L Koslowe
NPI 1023142395
$2,418.48
in general payments reported to CMS, 2019-2025
26 companies · $643 in 2025
The $643 reported for 2025 was more than what 77% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $125 · 2021: $204 · 2022: $284 · 2023: $369 · 2024: $544 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.99 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544.36 | 2019-2025 | |
| Janssen Biotech, INC. | $335.60 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $220.94 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $208.14 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $199.02 | 2019-2025 | Sucraid |
| Mirum Pharmaceuticals, INC. | $153.93 | 2022-2024 | Livmarli |
| E.R. Squibb & Sons, L.L.C. | $104.40 | 2022 | |
| Celltrion USA INC. | $72.20 | 2025 | Vegzelma |
| Coloplast Corp | $69.75 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.87 | 2024-2025 | Gattex, Eohilia |
| Travere Therapeutics, INC. | $62.07 | 2022-2023 | Cholbam |
| Sandoz INC. | $42.93 | 2023-2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $41.34 | 2025 | Tremfya |
| Cycle Pharmaceuticals INC | $40.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $37.33 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $31.79 | 2025 | |
| Celgene Corporation | $31.14 | 2023-2024 | Zeposia |
| Fresenius Kabi USA, LLC | $30.88 | 2023 | Idacio |
| Alfasigma USA, INC. | $28.44 | 2020 | |
| Amgen INC. | $27.19 | 2023 | Amjevita |
| Sanofi US Services INC. | $21.19 | 2025 | |
| Biocon Biologics INC | $19.80 | 2025 | Yesintek |
| Alcresta Therapeutics, INC. | $15.17 | 2023 | Relizorb |
| Cumberland Pharmaceuticals, INC. | $13.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oren Koslowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.